Dr. Stephanie Dusaban Gonzales

Stephanie Dusaban Gonzales Ph.D.

Stephanie Dusaban Gonzales Ph.D.
Los Angeles
+1 619 953 8773

Dr. Stephanie Dusaban Gonzales is a senior associate in Goodwin’s Life Sciences group. As a practicing patent attorney, Stephanie has extensive experience in leading patent prosecution, diligence, and related transactions, including capital raising, licensing, and initial public offerings.

Stephanie primarily focuses on representing growth-stage therapeutics companies spanning the breadth of life sciences in managing the patent strategy and prosecution of US and foreign patents. This includes pharmacology, antibody therapies, cell therapies, peptide-based therapeutics, CRISPR and genetic engineering, gene therapies, agriculture, and synthetic DNA tools.

Stephanie has also led IP diligence on both client-side capital raises and investor-side on investments totaling over $300 million.

Working extensively in the life sciences space, Stephanie utilizes her over ten years of biomedical research experience in pharmacology, cell signaling, drug discovery and translational medicine to support the holistic approach Goodwin brings to IP.



  • Advise Siren Biotechnology (gene therapy) in all IP matters
  • Advise Altis Biosystems (GI models for in vitro drug screens) on all IP matters
  • Advise BIOMILQ (cellular agriculture/synthetic biology) on all IP matters
  • Advise Metagenomi (gene editing) on IP matters
  • Advise Nogra (ASOs) on all ASO IP matters
  • Advise Triumvira (T cell therapies; Phase I clinical trials) on all IP matters 
  • Advised Twist Bioscience (synthetic DNA and antibodies) on all IP matters*
  • Advised Excision Bio (CRISPR) on all IP matters including $60 million Series A*
  • Advised Alastin Skincare (peptide formulations) on all IP matters including Galderma’s acquisition of Alastin*

Venture Capital

  • Advised SR One Capital Management on ADARx's $75 Million Series B*
  • Advised Novo Holdings on select IP matters*

IPOs, M&As, and Licensing Transactions

  • Advised Janux Therapeutics on patent matters related to IPO*

* Denotes experience prior to joining Goodwin.

Professional Experience

Stephanie began her career as a patent agent at Wilson Sonsini Goodrich Rosati. She was also an associate at Wilson Sonsini Goodrich Rosati for three years.

Stephanie received her PhD in Biomedical Sciences from the University of California, San Diego. She also worked as a postdoctoral fellow at the University of California, San Diego. Her PhD and postdoctoral work focused on G-protein coupled receptor signaling in astrocytes and its role in inflammation in the Central Nervous System. In doing so, she employed primary cell culture, disease animal models (Experimental Autoimmune Encephalomyelitis and traumatic brain injury), and advanced imaging (FRET).

Stephanie also participated in industry collaborations (Merck Serono) and authored and co-authored several peer-reviewed papers. She regularly participated in scientific conferences as an invited conference speaker and co-chaired the Gordon Research Seminar for graduate student and post-doctoral fellows with keynote speaker Nobel Price winner Brian Kobilka.




University of San Diego

(magna cum laude)

PhDBiomedical Sciences2015

University of California, San Diego

BABiological Sciences2009

Cornell University

(magna cum laude)



  • U.S. Patent and Trademark Office
  • California


  • Author, "Sphingosine 1-Phosphate Receptor 3 and RhoA Signaling Mediate Inflammatory Gene Expression in Astrocytes. J. Neuroinflammation," 2017
  • Author, "Thrombin Promotes Sustained Signaling and Inflammatory Gene Expression through the CDC25 and Ras Associating Domains of Phospholipase C-epsilon," 2015
  • Author, "PLCε Mediated Sustained Signaling Pathways," 2015
  • Author, "Phospholipase C-epsilon Links G-protein Coupled Receptor Activation to Inflammatory Astrocytic Responses," 2013
  • Co-Author, "Lysophospholipid Receptor Activation of RhoA and Lipid Signaling Pathways, 1831 Biochimica et Biophysica Acta," 2012
  • Co-Author, "The c-Myb Gene Target Neuromedin U Functions as a Novel Cofactor during the Early Stages of Erythropoiesis," 2011